ImmunoPrecise Antibodies Ltd.
IPA
$3.20
$0.5721.67%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.19% | -6.06% | -0.95% | -9.86% | 14.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.19% | -6.06% | -0.95% | -9.86% | 14.70% |
| Cost of Revenue | -28.18% | -10.27% | -16.35% | -2.10% | 46.71% |
| Gross Profit | 37.01% | -2.09% | 15.72% | -17.88% | -7.15% |
| SG&A Expenses | -10.03% | -3.48% | 6.07% | -9.64% | 32.84% |
| Depreciation & Amortization | -85.56% | -16.51% | -14.25% | -30.29% | -46.87% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.94% | -6.20% | -0.60% | -1.52% | 24.54% |
| Operating Income | 63.75% | 6.45% | -0.16% | -10.31% | -45.28% |
| Income Before Tax | 90.36% | -574.25% | -17.42% | -21.43% | -218.68% |
| Income Tax Expenses | 120.52% | -268.02% | -176.57% | -82.16% | -57.99% |
| Earnings from Continuing Operations | 88.28% | -663.19% | -5.40% | -14.05% | -242.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 88.28% | -663.19% | -5.40% | -14.05% | -242.71% |
| EBIT | 63.75% | 6.45% | -0.16% | -10.31% | -45.28% |
| EBITDA | 65.15% | -12.46% | -31.37% | -41.33% | -96.65% |
| EPS Basic | 93.18% | -499.48% | 6.07% | -5.28% | -221.88% |
| Normalized Basic EPS | 72.26% | 27.58% | -4.62% | -12.15% | -34.98% |
| EPS Diluted | 93.18% | -499.48% | 6.07% | -5.28% | -221.88% |
| Normalized Diluted EPS | 72.26% | 27.58% | -4.62% | -12.15% | -34.98% |
| Average Basic Shares Outstanding | 71.88% | 27.33% | 12.30% | 8.31% | 6.46% |
| Average Diluted Shares Outstanding | 71.88% | 27.33% | 12.30% | 8.31% | 6.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |